|
| Status |
Public on Oct 24, 2016 |
| Title |
AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors
|
| |
|
| Overall design |
NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tankyrase inhibitor) or a combination thereof
|
| |
|
| Contributor(s) |
Scarborough HA, Helfrich BA, Casas-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan A, Chan DC, Zhang Z, Vadym Zaberezhnyy V, Bunn PA, DeGregori J |
| Citation(s) |
27663586 |
| Submission date |
Apr 28, 2016 |
| Last update date |
May 15, 2019 |
| Contact name |
Jihye Kim |
| E-mail(s) |
kim.jihey@gmail.com
|
| Phone |
7209755448
|
| Organization name |
Cleveland Clinic
|
| Department |
Quantitative Health Sciences
|
| Street address |
9500 Euclid Ave.
|
| City |
Cleveland |
| State/province |
Ohio |
| ZIP/Postal code |
44195 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (16)
|
|
| Relations |
| BioProject |
PRJNA320000 |
| SRA |
SRP074154 |
Less...
More...